Fourteen patients were uptitrated from 75 to 150 mg of alirocumab sc. Q2W at week 12 based on week 8 LDL-C being ≥70 mg/dL and continued this dose until week 22 (last injection); however ...

Safety. Both evolocumab and alirocumab have been reported to be safe and well tolerated, with no report of causing hepatic transaminase elevation or hepatotoxicity. Nonserious injection site ...